AzTrials
AzTrials

Postoperative PainPhase 4NCT01735851

Comparison of Bilateral Thoracic Paravertebral Block to Thoracic Epidural Analgesia for Post Operative Analgesia in Patients Undergoing Abdominal Surgery

A Phase 4 study testing Thoracic epidural analgesia and Bilateral Paravertebral block in people with Postoperative Pain, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Pain following abdominal surgery is managed with the use of thoracic epidural analgesia (TEA) where the epidural is inserted in the spine at the level of scapula The risks due to TEA include difficulty with insertion, failure in up to 40% of patient in the perioperative period, fall in blood pressure and a rare… Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Postoperative Pain
What is being tested?
Thoracic epidural analgesia and Bilateral Paravertebral block
Could I receive a placebo?
No, everyone receives an active treatment
How many people
70 participants
Where
1 siteCanada
Study dates
Dec 2012to Dec 2014
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male and females of 18-85years of age, scheduled to undergo open abdominal surgeries.
  • ASA Class I, II, III -

Who cannot join

  • Patients with associated significant cardiac and respiratory disease
  • Patients with coexisting hematological disorder or with deranged coagulation parameters.
  • Patients with pre-existing major organ dysfunction such as hepatic and renal failure.
  • Patients with anatomical deformity of spine
  • Psychiatric illnesses
  • Emergency surgery
Show all 9Show fewer
  • Lack of informed consent.
  • Allergy to any of the drugs used in the study
  • Contraindications to epidural analgesia -

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • London Health Sciences Centre University Hospital

    London, Ontario, N6A 5A5

Other trials in Canada

About this study

Official title: Comparison of Bilateral Thoracic Paravertebral Block to Thoracic Epidural Analgesia for Post Operative Analgesia in Patients Undergoing Abdominal Surgery - A Randomized Open Label Study

Pain following abdominal surgery is managed with the use of thoracic epidural analgesia (TEA) where the epidural is inserted in the spine at the level of scapula The risks due to TEA include difficulty with insertion, failure in up to 40% of patient in the perioperative period, fall in blood pressure and a rare devastating complication of paralysis either due to bleeding or infection. Injury to spinal cord is also a feared complication. Therefore alternative techniques need to be evaluated. Paravertebral block (PVB) has been documented to provide pain relief following abdominal surgery using an earlier technique which posed the risk of puncture of the covering to the lung (pleura) resulting in pneumothorax. The current technique involves the use of curled catheters inserted using ultrasonography to lie outside the pleura where the nerves travel thus reducing the chances of pneumothorax and catheter migration. Objective of the current study is to compare the efficacy and safety of bilateral PVB with TEA. Patients undergoing bowel surgery will be randomized to receive thoracic epidural analgesia or bilateral thoracic paravertebral blocks. Pain scores during rest and coughing, failure and complication rates will be compared between the two groups.

Objective:

Read more

The objective of the investigators is to determine whether ultrasound (US)-guided bilateral thoracic paravertebral blocks (PVB) using curled catheter provides effective post-operative analgesia as compared to thoracic epidural analgesia in patients undergoing open abdominal bowel surgeries.

The primary outcome of this study will be the pain scores over the first 24 hours following open bowel surgeries.

Secondary outcomes include

  1. Analgesic consumption in the perioperative period,
  2. Block related data (block performance time, success rate, extent of sensory block, complications)
  3. Hemodynamic parameter every 6 hourly
  4. Incidence of side effects like nausea and pruritus scores, time to return of bowel activity

Hypothesis

Null Hypothesis: Primary.

Paravertebral blocks provide equal analgesia in the early postoperative period (first 24 hours of surgery) as compared to thoracic epidural analgesia in patients undergoing bowel surgeries by laparotomy.

Secondary

  1. The analgesic consumption between PVB and TEA is not different during the first 24 hours following surgery
  2. The block performance time, success rate and extent of sensory block with PVB are not different from that of TEA.
  3. Side effects and complications following bilateral PVB are not different from those occurring after TEA
Read the detailed description

A total of 70 patients with ASA physical status 1 to 3, scheduled for elective bowel surgery by laparotomy and deemed suitable to receive either thoracic paravertebral or epidural analgesia will be included in the study. Recruitment will take place in the preoperative clinic. Written informed consent for the participation in the study will be obtained at the visit to the preadmission clinic or in the preparation area at least 2 hours prior to the surgery. They will be randomized to one of two groups prior to the block procedure using a closed envelope system. All patients will be educated regarding the VRS scores on a scale of 0 to 10 where 0 is no pain and 10 is the worst pain ever experienced. All patients will receive perioperative multimodal analgesia using naproxen, gabapentin and acetaminophen.

All blocks will be performed in the block room using standard monitoring, sterile precautions and titrated intravenous sedation with fentanyl and midazolam. During block performance one anesthetist and one assistant will be present. Due to the necessity of handling the equipment these staff will not be blinded. All patients will receive supplemental oxygen.

Group 1: Group 1 will receive a catheter congruent TEA. The catheters will be inserted using ultrasound to assess level as well as the best space to insert the epidural catheter between T7 and T9. The epidural space will be identified using the loss of resistance technique. After a test dose to rule out intravascular and intrathecal placement of the catheter using 3mL of 2% lidocaine with 5mcg/mL of epinephrine, the initial block will be made with 0.25% bupivacaine 5 mL followed by 3 mL aliquots administered every 5 minutes to establish a block between T8 and T12. An infusion will be started at 8 mL/hour with 0.1 % bupivacaine with 10 microgram/mL of dilaudid and continued for 72 hours. Additional nurse administered boluses of 5-10mL of the standard solution will be allowed via the epidural catheter every 6hourly if needed for pain control followed by an increase in the basal infusion rate up to a maximum of 14mL/hr. Patients will be allowed to self-administer additional boluses of 3mL of the standard infusate every 20minutes (PCEA) as per the standard practice at this hospital. Time to initiate the block and the failures will be documented. If the block fails, patients will receive intravenous PCA with dilaudid and the patient will be dropped out of the study for efficacy data.

Group 2 will have bilateral PVB catheters inserted using the ultrasound. Patients will be in prone position and will receive intravenous sedation similar to Group 1. The T8 spine will be identified and marked counting from the lumbar area. A high-frequency linear ultrasound probe will be positioned in the T8/9 intercostal space with the transverse process and pleura in the field as well as the internal intercostal membrane. (about 2.5 cm lateral to the spinous process) Using ultrasound guidance and an in-plane approach, a 17 gauge Tuohy needle connected to 15 mL of 0.5% ropivacaine via an extension tubing will be inserted to puncture the internal intercostal membrane. Injection of local anesthetic will push the pleura away, which will be the end point of needle position (the current standard technique in the the investigators institution). A curved pigtail catheter will be inserted while observing its delivery extrapleurally and further 5mL of local anesthetic will be injected while observing further movement of pleura. A similar procedure will be done on the contralateral side at the same level. The catheter will be secured to the skin and covered with dermabond and tegaderm. Following this, 0.2% ropivacaine will be infused at a rate of 7 mlLhr via each catheter for the next 72 hours post-operatively. They will also receive intravenous patient controlled analgesia with dilaudid at a dose of 0.2mg with a lock out of 6 mins. Additional nurse administered boluses of 5-10mL of ropivacaine 0.2% via the paravetebral catheters will be permitted every 6 hourly to the side of maximal pain. The position of the catheter will be confirmed on the routine post-operative chest x ray following the injection of contrast (Isovue: 2 mL). The sensory block extent will be documented at 15 minutes after the initial injection and prior to moving the patient to the OR. Time to initiate the block and the failure rate will be documented.

US image of paravertebral space before and after LA injection (IIM: internal intercostal membrane; TP: transverse process; LA: local anesthetic)

As soon as the arterial line is inserted in the operating room for monitoring purposes, 10mL of blood will be collected for measuring plasma ropivacaine levels. This measurement will be repeated on arrival in the PACU along with routine postoperative arterial blood gas analysis. Plasma ropivacaine level will be measured on postoperative day 1 at 6AM with the blood drawn along with routine postoperative blood work (venous sample)

Cases with a failure to establish a block 30 minutes after local anesthetic injection will be considered as block failure and the patient will be excluded from the efficacy part of the study. These patients will receive intravenous patient controlled analgesia. Once the effectiveness and level of the block is confirmed the patient will be moved to the operating room for the surgery under standardized general anesthesia using fentanyl 2-3µg/Kg, propofol 2 mg/kg and rocuronium 0.8-1.0 mg/kg for intubation followed by maintenance with desflurane in air-oxygen mixture. Vasopressors (Ephedrine and phenylephrine) will be administered as needed to control hemodynamics and the total dose used will be recorded.

The patients will be assessed for pain during rest and coughing/activity immediately after the surgery, every 15 minutes for first 2 hrs and 6 hourly thereafter until 24 hours after the removal of epidural or block catheters. Patients whose VRS scores are higher than 5/10 in PACU, apart from getting a bolus in the epidural or PVB may also receive IV Hydromorphone 0.2 mg every 5 minutes till pain subsides to a score of 3/10. Nausea will be documented using a categorical scale (none, mild, moderate and severe), pruritus scores will be recorded every 12 hours (categorical scale, none, mild, moderate and severe). Time to onset of bowel sounds, time to first flatus and time to first bowel movement would also be recorded with time 0 being the arrival time in PACU. Post-operative hemodynamic changes, blood pressure and urine output will be documented every 6 hours. Duration of significant hypotension will be computed from the nursing chart, significant hypotension being systolic BP less than 90 mm Hg. Patient satisfaction will be documented on a visual analogue scale where 0 is totally dissatisfied and 100 is totally satisfied. Adverse events such as local anesthetic toxicity, wound infection, dehiscence, urinary retention, cognitive dysfunction and neurological deficits will be prospectively collected. The failure rate of both the techniques and the number of attempts will also be recorded.

This is an open label study to document the effectiveness of bilateral PVB in bowel surgeries. The investigators plan to do a double blind study following the present study if the results are encouraging. The second concern is that 2 different local anesthetics are used for the 2 limbs but at equianalgesic concentrations for the infusion.

Being tested
Thoracic epidural analgesia, Bilateral Paravertebral block
Keywords
Thoracic epidural analgesia, Paravertebral block, pain, postoperative
Medical subject headings
Pain, Postoperative, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Thoracic epidural analgesiaDrug

    Also called Thoracic Epidural Anesthesia

  • Bilateral Paravertebral blockProcedure or surgery

Study groups in NCT01735851
Study groupRoleWhat they receive
Thoracic epidural analgesiaActive comparatorGroup 1 will receive a catheter congruent TEA. The epidural space will be identified using the loss of resistance technique. After a test dose to rule out intravascular and intrathecal placement of the catheterthe initial block will be made with 0.25% bupivacaine 5 mL followed by 3 mL aliquots administered every 5 minutes to establish a block between T8 and T12. An infusion will be started at 8 mL/hour with 0.1 % bupivacaine with 10microgram/mL of dilaudid and continued for 72 hours. Additional nurse administered boluses of 5-10mL of the standard solution will be allowed via the epidural catheter every 6hourly for poor pain control followed by an increase in the basal infusion rate up to a maximum of 14mL/hr. Patients will be allowed to self administer additional boluses of 3mL of the standard infusate every 20minutes (PCEA)
Receives: Drug: Thoracic epidural analgesia
Bilateral Paravertebral blockExperimentalGroup 2 will have bilateral PVB catheters inserted using the ultrasound with patients prone. A high-frequency linear probe will used to visualize the transverse process, pleura and the internal intercostal membrane. A 17 guage Tuohy needle will be inserted to puncture the internal intercostal membrane. Injection of local anesthetic will push the pleura away, which will be the end point of needle position. A curved pigtail catheter will be inserted and further 5mL of local anesthetic will be injected while observing further movement of pleura. A similar procedure will be done on the contralateral side at the same level. Infusion of 0.2% ropivacaine will be continued for the next 72 hours. They will also receive IVPCA and additional nurse administered boluses of 5-10mL of ropivacaine 0.2% in the PVB every 6 hourly to the side of maximal pain.
Receives: Procedure: Bilateral Paravertebral block

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Postoperative pain scores at rest and on coughing in the first 24 postoperative hours

    Pain scores at rest and coughing will be documented every 15 minutes for the first 2 hours in PACU and thereafter every 6 hourly until the first 24 hours. Patients may receive intravenous dilaudid boluses in the PACU if the pain scores are greater than 5. patients will be receiving IVPCA or PCEA depending on the group allocation in the PACU. The total dose of narcotic used will be documented.

    Measured: From arrival in PACU until 24 hours of arrival in the PACU

Secondary outcomes (1)
  1. total pain scores till 72 hours postoperatively

    Pain scores at rest and coughing will be documented every 15 minutes for the first 2 hours in PACU and thereafter every 6 hourly until the block catheters are removed at 72 hours. Patients may receive intravenous dilaudid boluses if the pain scores are greater than 5. The total dose of narcotic used will be documented.

    Measured: from arrival in PACU to 3rd postoperative day (72 hours)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Nov 2012 (estimated)
  2. Study startDec 2012
  3. Primary completionDec 2014
  4. Study completionDec 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
70 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01735851
Sponsor's protocol ID
HSREB UWO 103035
Status last verified
Aug 2015
First submitted
26 Oct 2012
Last updated
1 Sep 2015
Results posted
No
Data monitoring committee
No

Publications

  • Finucane BT, Ganapathy S, Carli F, Pridham JN, Ong BY, Shukla RC, Kristoffersson AH, Huizar KM, Nevin K, Ahlen KG; Canadian Ropivacaine Research Group. Prolonged epidural infusions of ropivacaine (2 mg/mL) after colonic surgery: the impact of adding fentanyl. Anesth Analg. 2001 May;92(5):1276-85. doi: 10.1097/00000539-200105000-00038.

    PubMed 11323362
  • Luyet C, Meyer C, Herrmann G, Hatch GM, Ross S, Eichenberger U. Placement of coiled catheters into the paravertebral space. Anaesthesia. 2012 Mar;67(3):250-5. doi: 10.1111/j.1365-2044.2011.06988.x.

    PubMed 22321080
  • Sondekoppam RV, Uppal V, Brookes J, Ganapathy S. Bilateral Thoracic Paravertebral Blocks Compared to Thoracic Epidural Analgesia After Midline Laparotomy: A Pragmatic Noninferiority Clinical Trial. Anesth Analg. 2019 Sep;129(3):855-863. doi: 10.1213/ANE.0000000000004219.

    PubMed 31425230

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Thoracic epidural analgesia and Bilateral Paravertebral block in people with Postoperative Pain, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Sep 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Postoperative pain scores at rest and on coughing in the first 24 postoperative hours (time frame: From arrival in PACU until 24 hours of arrival in the PACU). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01735851, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in